Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
DARUNAVIR
MANTRA PHARMA INC
J05AE10
DARUNAVIR
600MG
TABLET
DARUNAVIR 600MG
ORAL
30
Prescription
HIV PROTEASE INHIBITORS
Active ingredient group (AIG) number: 0151656003; AHFS:
APPROVED
2021-11-10
_M-DARUNAVIR (Darunavir Tablets, House Std.)_ Page 1 of 99 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR M-DARUNAVIR Darunavir Tablets Tablets, 400 mg, 600 mg and 800 mg, Oral House Standard Human Immunodeficiency Virus (HIV) Protease Inhibitor Mantra Pharma Inc. 9150 Leduc Blvd., Suite 201 Brossard, Quebec J4Y 0E3 Date of Initial Authorization: NOV 10, 2021 Date of Revision MAY 04, 2023 Submission Control Number: 274446 _M-DARUNAVIR (Darunavir Tablets, House Std.)_ Page 2 of 99 RECENT MAJOR LABEL CHANGES Not applicable TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................. 4 1 INDICATIONS ........................................................................................................................ 4 1.1 Pediatrics .................................................................................................................... 4 1.2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ......................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ....................................................................................... 5 4.1 Dosing Considerations ................................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment ........................................................... 5 4.5 Missed Dose ............................................................................................................... 7 5 OVERDOSAGE .......... Կարդացեք ամբողջական փաստաթուղթը